These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26311555)

  • 1. Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.
    Ekins S; Litterman NK; Lipinski CA; Bunin BA
    Pharm Res; 2016 Jan; 33(1):194-205. PubMed ID: 26311555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?
    Goldman RC
    Tuberculosis (Edinb); 2013 Nov; 93(6):569-88. PubMed ID: 24119636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models.
    Ekins S; Reynolds RC; Franzblau SG; Wan B; Freundlich JS; Bunin BA
    PLoS One; 2013; 8(5):e63240. PubMed ID: 23667592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A collaborative database and computational models for tuberculosis drug discovery.
    Ekins S; Bradford J; Dole K; Spektor A; Gregory K; Blondeau D; Hohman M; Bunin BA
    Mol Biosyst; 2010 May; 6(5):840-51. PubMed ID: 20567770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets.
    Ekins S; Freundlich JS
    Pharm Res; 2011 Aug; 28(8):1859-69. PubMed ID: 21547522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.
    Ekins S; Freundlich JS; Hobrath JV; Lucile White E; Reynolds RC
    Pharm Res; 2014 Feb; 31(2):414-35. PubMed ID: 24132686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis.
    Ekins S; Kaneko T; Lipinski CA; Bradford J; Dole K; Spektor A; Gregory K; Blondeau D; Ernst S; Yang J; Goncharoff N; Hohman MM; Bunin BA
    Mol Biosyst; 2010 Nov; 6(11):2316-2324. PubMed ID: 20835433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis.
    Forbes L; Ebsworth-Mojica K; DiDone L; Li SG; Freundlich JS; Connell N; Dunman PM; Krysan DJ
    PLoS One; 2015; 10(6):e0129234. PubMed ID: 26098625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cheminformatics approaches to analyze diversity in compound screening libraries.
    Akella LB; DeCaprio D
    Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of NMR in leveraging dynamics and entropy in drug design.
    Dubey A; Takeuchi K; Reibarkh M; Arthanari H
    J Biomol NMR; 2020 Nov; 74(10-11):479-498. PubMed ID: 32720098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale bioactivity analysis of the small-molecule assayed proteome.
    Backman TW; Evans DS; Girke T
    PLoS One; 2017; 12(2):e0171413. PubMed ID: 28178331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do enthalpy and entropy distinguish first in class from best in class?
    Freire E
    Drug Discov Today; 2008 Oct; 13(19-20):869-74. PubMed ID: 18703160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Toxicology Methods in Chemical Library Design and High-Throughput Screening Hit Validation.
    Hevener KE
    Methods Mol Biol; 2018; 1800():275-285. PubMed ID: 29934898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A look at ligand binding thermodynamics in drug discovery.
    Claveria-Gimeno R; Vega S; Abian O; Velazquez-Campoy A
    Expert Opin Drug Discov; 2017 Apr; 12(4):363-377. PubMed ID: 28276703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Informatics resources for tuberculosis--towards drug discovery.
    Sundaramurthi JC; Brindha S; Reddy TB; Hanna LE
    Tuberculosis (Edinb); 2012 Mar; 92(2):133-8. PubMed ID: 21943870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying thermodynamic profiling in lead finding and optimization.
    Klebe G
    Nat Rev Drug Discov; 2015 Feb; 14(2):95-110. PubMed ID: 25614222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the BioAssay Ontology for analyzing high-throughput screening data.
    Zander Balderud L; Murray D; Larsson N; Vempati U; Schürer SC; Bjäreland M; Engkvist O
    J Biomol Screen; 2015 Mar; 20(3):402-15. PubMed ID: 25512330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-based approaches to the discovery of kinase inhibitors.
    Mortenson PN; Berdini V; O'Reilly M
    Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.